DermaXon

DX416：一種治療皮膚疼痛和瘙癢的新型療法，該療法可應用於市面上的大量皮膚病，包括：皮膚疼痛、皮膚搔癢及皮膚罕見病等，可由DX416的體內試驗見其減輕體內外疼痛和瘙癢症狀的有效性。DX416的製造成本不高，作為孤兒藥可獲得稅收抵免及費用減免，有效降低成本。

DX308：用於治療罕見的皮膚病—先天性魚鱗癬的新療法，該療法針對尚未獲得 FDA 批准藥物的罕見疾病市場，可由DX308 的體內試驗見其有效性，並且不會引起紅斑或毒性，DX308本身作為孤兒藥還可獲得稅收抵免及費用減免，有效降低成本。

DX814：用於治療自體免疫性或超免疫性疾病。透過納摩爾抑製劑針對一種可藥物化的激酶 RIOK3，該激酶可調節干擾素的合成。

DX416: a novel treatment for skin pain and pruritus. DX416 efficacy and tolerability: In vivo administration of DX416 has shown high efficacy at reducing pain and pruritus in vivo and ex vivo. Cost: No expensive manufacturing cost, tax credit and fees waivers will be obtained with the orphan drug status. Market: Skin pain and pruritus are associated with a large number of skin diseases including rare diseases

DX308: DermaXon is developing DX308, a novel patent protected treatment of the rare skin disease, congenital ichthyosis. In vivo administration of DX308 has shown high efficacy without inducing erythema or toxicity. Cost: No expensive manufacturing cost, tax credit and fees waivers will be obtained with the orphan drug status. Market: Targets a rare disease market without FDA approved treatments.

DX814: DermaXon has identified a nanomolar inhibitor (DX814) targeting an understudied druggable kinase RIOK3 that regulates interferon synthesis for the treatment of autoimmune or hyperimmune response disorders.